Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
33 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Walvax Biotechnology Co., Ltd. (Walvax) is a biopharmaceutical company that conducts research and development services. The company develops, produces and markets bio-medical products including vaccines, blood products and others. Its products include Haemophilus influenzae vaccine for the prevention of infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis; Group A, C meningococcal polysaccharide vaccine for preventing diseases such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease.

Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major r

  
Source:
Document ID
GDPH347602D
Country
Industry
Ticker
300142=CN
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Walvax Biotechnology Co., Ltd., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Walvax Biotechnology Co., Ltd., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Walvax Biotechnology Co., Ltd., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Walvax Biotechnology Co., Ltd., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Walvax Biotechnology Co., Ltd., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 201692
Walvax Biotechnology Co., Ltd., Pharmaceuticals &Healthcare, Deal Details1120
  Equity Offering111
    Walvax Biotech Plans to Raise up to USD72.9 Million in Private Placement of Shares111
  Debt Offering121
    Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million121
    Walvax Biotechnology Plans Debt Offering For US$398 Million131
    Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million141
  Acquisition151
    Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million151
    Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million161
    Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million171
    Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million181
    Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million191
    Walvax Biotech Acquires Three Biomedical Companies201
    Walvax Biotechnology To Acquire 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group For US$47.5 Million212
    Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million231
    Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million241
    Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million251
    Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million261
    Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million271
    Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million282
    Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million301
Walvax Biotechnology Co., Ltd. - Key Competitors311
Locations And Subsidiaries321
  Head Office321
  Other Locations &Subsidiaries321
Appendix331
  Methodology331
  About GlobalData331
  Contact Us331
  Disclaimer331

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Walvax-Biotechnology-Co-Ltd-300142-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-24994>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Walvax-Biotechnology-Co-Ltd-300142-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-24994>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research